EP3103445A1 — Ulipristal acetate tablets
Assigned to Laboratoire HRA Pharma SAS · Expires 2016-12-14 · 9y expired
What this patent protects
The invention relates to a pharmaceutical tablet for oral administration comprising ulipristal acetate together with the following excipients: at least one diluent in an amount of 50 to 98.5 wt%, at least one binding agent in an amount of 0 to 10 wt%, at least one disintegrating …
USPTO Abstract
The invention relates to a pharmaceutical tablet for oral administration comprising ulipristal acetate together with the following excipients: at least one diluent in an amount of 50 to 98.5 wt%, at least one binding agent in an amount of 0 to 10 wt%, at least one disintegrating agent in an amount of 0.5 to 10 wt%, and at least one lubricant in an amount of 0 to 10 wt%.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.